{"address1": "1-8, Doshomachi 3-chome", "address2": "Chuo-ku", "city": "Osaka", "zip": "541-0045", "country": "Japan", "phone": "81 6 6202 2161", "fax": "81 6 6229 9596", "website": "https://www.shionogi.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.", "fullTimeEmployees": 5680, "companyOfficers": [{"maxAge": 1, "name": "Dr. Isao  Teshirogi Ph.D.", "age": 64, "title": "CEO, President & Representative Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 291000000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Susumu  Mitsumori", "title": "Vice President of Finance & Accounting Department", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kazuhiro  Hatanaka", "title": "Senior Executive Officer & Senior VP of Administration Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Takeshi  Shiota Ph.D.", "title": "Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshimasa  Kyokawa", "title": "Vice President of Corporate Communications & Secretary Office", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Yoshihiro  Furuya", "title": "Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kohji  Hanasaki Ph.D.", "title": "Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A.  Keller Ph.D.", "age": 58, "title": "Senior Executive Officer and Senior VP of R&D Supervisory Unit", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Akira  Kato Ph.D.", "title": "Corporate Officer & President of Shionogi Pharma Co., Ltd", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ryuichi  Kiyama Ph.D.", "title": "Senior Executive Officer & Senior VP of Corporate Strategy Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 1, "compensationRisk": 1, "shareHolderRightsRisk": 3, "overallRisk": 1, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7852.0, "open": 7837.0, "dayLow": 7813.0, "dayHigh": 7879.0, "regularMarketPreviousClose": 7852.0, "regularMarketOpen": 7837.0, "regularMarketDayLow": 7813.0, "regularMarketDayHigh": 7879.0, "dividendRate": 150.0, "dividendYield": 0.0191, "exDividendDate": 1711584000, "payoutRatio": 0.2834, "fiveYearAvgDividendYield": 1.78, "beta": 0.36, "trailingPE": 14.833152, "forwardPE": 15.517821, "volume": 147900, "regularMarketVolume": 147900, "averageVolume": 1175400, "averageVolume10days": 1449480, "averageDailyVolume10Day": 1449480, "bid": 7844.0, "ask": 7849.0, "marketCap": 2258609897472, "fiftyTwoWeekLow": 5718.0, "fiftyTwoWeekHigh": 8137.0, "priceToSalesTrailing12Months": 5.3124137, "fiftyDayAverage": 7345.7, "twoHundredDayAverage": 6754.155, "trailingAnnualDividendRate": 150.0, "trailingAnnualDividendYield": 0.019103413, "currency": "JPY", "enterpriseValue": 1780216496128, "profitMargins": 0.36330003, "floatShares": 287212033, "sharesOutstanding": 287720992, "heldPercentInsiders": 0.04665, "heldPercentInstitutions": 0.6109, "impliedSharesOutstanding": 288383008, "bookValue": 4149.663, "priceToBook": 1.8917198, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.635, "netIncomeToCommon": 154457997312, "trailingEps": 529.22, "forwardEps": 505.87, "pegRatio": 2.0, "enterpriseToRevenue": 4.187, "enterpriseToEbitda": 10.523, "52WeekChange": 0.3338449, "SandP52WeekChange": 0.32311738, "lastDividendValue": 75.0, "lastDividendDate": 1711584000, "exchange": "JPX", "quoteType": "EQUITY", "symbol": "4507.T", "underlyingSymbol": "4507.T", "shortName": "SHIONOGI & CO", "longName": "Shionogi & Co., Ltd.", "firstTradeDateEpochUtc": 946944000, "timeZoneFullName": "Asia/Tokyo", "timeZoneShortName": "JST", "uuid": "0666cc67-bf78-330a-92e9-eb098e3fe25d", "messageBoardId": "finmb_875364", "gmtOffSetMilliseconds": 32400000, "currentPrice": 7850.0, "targetHighPrice": 8870.0, "targetLowPrice": 5400.0, "targetMeanPrice": 7697.5, "targetMedianPrice": 8000.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 507772010496, "totalCashPerShare": 1767.192, "ebitda": 169165996032, "totalDebt": 9843999744, "quickRatio": 5.744, "currentRatio": 6.568, "totalRevenue": 425157001216, "debtToEquity": 0.811, "revenuePerShare": 1453.645, "returnOnAssets": 0.07224, "returnOnEquity": 0.1336, "freeCashflow": 63832375296, "operatingCashflow": 128536002560, "earningsGrowth": -0.627, "revenueGrowth": -0.433, "grossMargins": 0.85867995, "ebitdaMargins": 0.39789, "operatingMargins": 0.38233003, "financialCurrency": "JPY", "trailingPegRatio": null}